Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - Cervarix, August 5, 2009

Record of Telephone Conversation 

STN Number: 125259/0 

Manufacturer: GlaxoSmithKline Biologicals 

Product: Human Papillomavirus Vaccine, ASO4 Adjuvant-Adsorbed 

To: File 

From: Helen S. Gemignani, Regulatory Project Manager Subject: Information Request Clarification 

Telecon Date: August 5, 2009 

Telecon Time: 3:32pm 

Telecon Initiated: Laura Montague 

Contact Phone: 610 787-3726 


Summary of Telecon 

We acknowledge receipt of your July 31, 2009, response to our July 26, 2009 Information Request, in which you provided four tables of information in regard to persistent infection. We request that you provide these analyses for the Total Vaccinated Cohort, as in Table 97, p. 355, of the clinical study for HPV-008. 

End of Teleconference 

Action Items 

• GSK to revise response and resubmit as advised. 

FDA Participants 

• Laura Montague 

GSK Participants 

• Matt Whitman

Page Last Updated: 04/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English